Approaches to multidrug resistance reversal

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Multidrug resistance (MDR) is a major challenge in cancer chemotherapy, characterized by cancer cells expelling anticancer drugs.
• Overexpression of P-glycoprotein, a membrane glycoprotein, actively transports drugs out of cells, leading to MDR.
• Existing MDR reversal agents often exhibit high toxicity, limiting their clinical application.

Purpose of the Study:

• To review compounds that inhibit P-glycoprotein and reverse MDR.
• To evaluate the efficacy and toxicity of novel MDR reversal agents in clinical trials.
• To discuss the ongoing research and future directions in overcoming drug resistance in cancer therapy.

Main Methods:

• In vitro studies demonstrating P-glycoprotein inhibition and MDR reversal.
• Clinical trials evaluating MDR reversal agents in hematological malignancies and solid tumors.
• Review of existing literature on MDR mechanisms and therapeutic strategies.

Main Results:

• Compounds like dexverapamil, valspodar, VX-710, and GF-120918 have shown potential for MDR reversal with acceptable toxicity.
• Positive results observed primarily in hematological malignancies, with some efficacy in solid tumors.
• Phase II and III clinical trials are ongoing to assess the survival benefits of combining MDR reverter agents with conventional chemotherapy.

Conclusions:

• Novel MDR reversal agents demonstrate promise in sensitizing resistant cancers.
• Further rigorous clinical evaluation is necessary to confirm the benefits of MDR reversal agents in improving patient survival.
• MDR is a complex, multifactorial phenomenon requiring comprehensive therapeutic strategies.